Evidence map›Paper›PMID 39914892›Full record

ArticleNano letters2025

Engineered Shape-Tunable Copper-Coordinated Nanoparticles for Macrophage Reprogramming.

Han Gao, Ruoyu Cheng, Inês Cardoso, Maria Lobita, Idaira Pacheco-Fernández, Raquel Bártolo, Lígia R Rodrigues, Jouni Hirvonen, Hélder A Santos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Clinical translation and landscape of copper nanoparticles.Drug delivery and translational research · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Han GaoDepartment of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Ruoyu ChengDepartment of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Inês CardosoDepartment of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Maria LobitaDepartment of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Idaira Pacheco-FernándezDepartment of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Raquel BártoloDepartment of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands.ORCID 0000-0002-5002-4225
Lígia R RodriguesCEB - Centre of Biological Engineering, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal.ORCID 0000-0001-9265-0630
Jouni HirvonenDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland.ORCID 0000-0002-5029-1657
Hélder A SantosDepartment of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands.ORCID 0000-0001-7850-6309

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immune system safeguards as primary defense by recognizing nanomaterials and maintaining homeostasis, gaining a deeper understanding of these interactions may change the treating paradigm of immunotherapy. Here, we adopted copper as the principal component of nanoparticles (NPs), given its features of coordination with different benezenecarboxylate ligands to form metal-organic frameworks and complexes with distinct morphologies. As a result, four types of shape-tunable copper-coordinated NPs (CuCNPs) are developed: cuboctahedron, needle, octahedron, and plate NPs. Biocompatibility of CuCNPs varies across different cell lines (RAW264.7, THP-1, HEK 293 and HeLa) in a shape-dependent manner, with needle-shaped CuCNPs showing pronounced cytotoxicity (IC50:104.3 μg mL

Indexed as

Cellular ReprogrammingCopperMacrophagesMetal NanoparticlesMetal-Organic FrameworksAnimalsHEK293 CellsHeLa CellsHumansMiceParticle SizeRAW 264.7 CellsTHP-1 CellsCopperMetal-Organic FrameworksCopper coordination nanocomplexesImmune responseMacrophage reprogrammingNanoparticlesShape-tunable

Identifiers

PMID39914892
PMCPMC11849021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.